한글목차

약물 재창출 서비스 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 342억 달러에서 2026년에는 361억 9,000만 달러로, CAGR 5.8%로 확대될 것으로 예상됩니다. 지난 수년간의 성장은 의약품 연구개발비 증가, 풍부한 기존 의약품 데이터 활용 가능성, 임상시험 실패 건수 증가, 신속한 의약품 개발 사이클에 대한 수요 증가, 컴퓨터 지원 신약개발의 조기 도입 등이 주요 요인으로 꼽힙니다.

약물 재창출 서비스 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 459억 2,000만 달러에 달하고, CAGR은 6.1%가 될 전망입니다. 예측 기간 동안의 성장 요인으로는 비용 효율적인 의약품 개발에 대한 수요 증가, AI 기반 신약 개발 도구의 도입 확대, 희귀 및 고아 질환에 대한 관심 증가, 데이터 기반 임상 연구 확대, 재사용 의약품에 대한 규제 당국의 수용성 향상 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 AI 기반 약물 재사용 플랫폼의 활용 증가, 임상시험 실패 약물의 재평가에 대한 관심 증가, 신약개발의 실제 데이터 통합 확대, 정밀의료 지향적 재사용 확대, 제약기업과 이종산업 간 협력 강화 등을 꼽을 수 있습니다.

향후 몇 년 동안 헬스케어 지출의 증가는 약물 재창출 서비스 시장의 성장을 견인할 것으로 예상됩니다. 헬스케어 지출은 예방, 치료, 재활, 관리 등 헬스케어 서비스에 할당된 총 자금을 의미합니다. 이러한 지출은 주로 기술 발전으로 인한 의료비 상승과 의료 서비스 수요 증가로 인해 증가하고 있습니다. 의료비 지출의 증가는 약물 재배치 서비스에 긍정적인 영향을 미칩니다. 자금 증액으로 추가 임상시험 및 조사가 가능해져 기존 약물의 새로운 치료 용도 발굴이 가속화될 수 있기 때문입니다. 예를 들어, 영국 정부 기관인 통계청(ONS)에 따르면, 2024년 5월 기준 2022년부터 2023년까지 명목상 총 의료비 지출은 5.6%의 눈에 띄는 증가세를 보였습니다. 따라서 의료비 지출의 증가는 의약품 전환 서비스 시장의 성장에 기여하고 있다고 할 수 있습니다.

약물 재창출 서비스 시장에서 사업을 전개하는 주요 기업들은 계산기를 이용한 약물 재창출 시스템 등 인공지능(AI)을 활용한 약물 재창출의 중요성을 강조하고 있습니다. 이는 문헌과 생물학적 데이터를 AI 기반 분석을 통해 체계적으로 분석하여 기존 의약품의 새로운 치료 용도를 찾아내는 것입니다. 컴퓨터 지원 신약 리포지셔닝 시스템이란 인공지능, 머신러닝, 데이터 마이닝을 활용하여 기존 의약품, 화합물, 생물학적 데이터를 체계적으로 분석하는 기술 기반입니다. 예를 들어, 2024년 11월 일본 기업 우베산업(UBE)과 프론테오(FRONTEO)가 공동 창조 프로젝트를 시작했습니다. 이번 공동 프로젝트는 우베코산과 프론테오의 전문성을 결합하여 신약개발 리포지셔닝을 추진하기 위한 협력 프레임워크를 제공하게 됩니다. 이를 통해 건식 연구(데이터 분석)와 습식 연구(생물학적 시험)의 원활한 연계를 촉진하고, 가설 생성에서 실험적 검증으로의 전환을 강화합니다. 프론테오의 AI 기반 '신약개발 AI 팩토리'와 'KIBIT' 기술을 활용하여, 본 프로젝트는 지금까지 보고되지 않은 질병과 분자 간의 연관성을 체계적으로 규명합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Drug repositioning service focuses on systematically discovering new therapeutic applications for existing drugs, enabling pharmaceutical companies to enhance the value of their current drug portfolios while reducing the risks linked to developing entirely new compounds. By utilizing existing clinical data and research, drug repositioning services help optimize the drug development process, considerably lowering the time and cost needed to deliver effective treatments to patients.

The main types of drug repositioning services include generic drugs and drugs that failed in clinical trials. Generic drugs are medications that contain the same active ingredients, strength, dosage form, and therapeutic effect as brand-name drugs but are generally available at lower costs. The therapeutic areas include oncology, neurology, infectious diseases, cardiovascular diseases, and other therapeutic areas. These are utilized by various end users, including pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic research institutions, hospitals, and ambulatory surgical centers.

Tariffs are impacting the drug repositioning service market by increasing costs associated with imported computational infrastructure, specialized software licenses, laboratory reagents, and cross-border research services. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on global data platforms and outsourced research activities, while Asia-Pacific faces increased costs for collaborative research services. These tariffs are elevating overall project expenses and slowing multinational repositioning programs. However, they are also encouraging regional research partnerships, domestic service provider growth, and localized drug development strategies.

The drug repositioning service market research report is one of a series of new reports from The Business Research Company that provides drug repositioning service market statistics, including drug repositioning service industry global market size, regional shares, competitors with a drug repositioning service market share, detailed drug repositioning service market segments, market trends and opportunities, and any further data you may need to thrive in the drug repositioning service industry. This drug repositioning service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug repositioning service market size has grown strongly in recent years. It will grow from $34.2 billion in 2025 to $36.19 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing pharmaceutical r&d costs, availability of extensive legacy drug data, rising number of failed clinical trials, growing demand for faster drug development cycles, early adoption of computational drug discovery.

The drug repositioning service market size is expected to see strong growth in the next few years. It will grow to $45.92 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing demand for cost-efficient drug development, rising adoption of ai-driven discovery tools, growing focus on rare and orphan diseases, expansion of data-driven clinical research, increasing regulatory acceptance of repurposed drugs. Major trends in the forecast period include increasing use of ai-based drug repurposing platforms, rising focus on failed clinical drug re-evaluation, growing integration of real-world evidence in drug discovery, expansion of precision medicine-oriented repositioning, enhanced collaboration between pharma and cros.

The increase in healthcare expenditures is expected to drive the growth of the drug repositioning service market in the coming years. Healthcare expenditures refer to the total funds allocated to health services, including prevention, treatment, rehabilitation, and administration. These expenditures are rising mainly due to higher medical costs fueled by technological advancements and growing demand for healthcare services. Increased healthcare spending benefits drug repositioning services, as more funding enables additional clinical trials and research, speeding up the discovery of new therapeutic applications for existing drugs. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a notable increase of 5.6% in nominal terms from 2022 to 2023. Therefore, the rise in healthcare expenditures is contributing to the growth of the drug repositioning service market.

Major companies operating in the drug repositioning service market are emphasizing the use of artificial intelligence (AI) in drug repositioning, such as computational drug repositioning systems, which systematically identify new therapeutic uses for existing drugs through AI-driven analysis of literature and biological data. A computational drug repositioning system is a technology-based platform that utilizes artificial intelligence, machine learning, and data mining to systematically analyze existing drugs, compounds, and biological data. For example, in November 2024, UBE and FRONTEO, Japanese companies, initiated a co-creation project. The co-creation project provides a collaborative framework that combines expertise from both UBE and FRONTEO to advance drug repositioning efforts. It facilitates seamless interaction between dry research (data analysis) and wet research (biological testing), enhancing the transition from hypothesis generation to experimental validation. By leveraging FRONTEO's AI-driven Drug Discovery AI Factory and KIBIT technology, the project systematically uncovers previously unreported relationships between diseases and molecules.

In January 2024, Cosmos Health Inc., a US-based healthcare group, acquired the Cloudscreen platform from Cloudpharm P.C. for an undisclosed amount. Through this acquisition, Cosmos Health Inc. aims to advance drug repurposing initiatives by utilizing Cloudscreen's AI platform to identify new therapeutic applications for existing drugs more effectively. Cloudpharm P.C. is a Greece-based company that provides drug repositioning services.

Major companies operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited

North America was the largest region in the drug repositioning service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repositioning service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug repositioning service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug repositioning service market consists of revenues earned by entities by providing services such as target validation, pharmacovigilance support, formulation optimization, drug combination analysis, and post-marketing surveillance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Repositioning Service Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drug repositioning service market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug repositioning service ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug repositioning service market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Generic Drugs; Clinical Trial Failed Drugs
• 2) By Therapeutic Area: Oncology; Neurology; Infectious Diseases; Cardiovascular Diseases; Other Therapeutic Area
• 3) By End-User: Pharmaceutical Companies; Biotechnology Firms; Contract Research Organizations (CROs); Academic Research Institutions; Hospitals And Ambulatory Surgical Centers.
• Subsegments:
• 1) By Generic Drugs: Small Molecule Drugs; Biologics; Biosimilars; Peptide-Based Drugs
• 2) By Clinical Trial Failed Drugs: Phase I Failed Drugs; Phase II Failed Drugs; Phase III Failed Drugs; Safety-Related Failed Drugs; Efficacy-Related Failed Drugs
• Companies Mentioned: Recursion Pharmaceuticals Inc.; Excelra; LifeArc; Cosmos Health Inc.; Fios Genomics; Insilico Medicine Inc.; Melior Discovery; Delta4; Acubiosys; VeriSIM Life; BioXcel Therapeutics Inc.; Pharnext S.S.; NuMedii; GVK Biosciences; Plex Research; Paradigm Biopharmaceuticals; BenevolentAI Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Drug Repositioning Service Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Drug Repositioning Service Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Drug Repositioning Service Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Drug Repositioning Service Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Use Of Ai-Based Drug Repurposing Platforms
  • 4.2.2 Rising Focus On Failed Clinical Drug Re-Evaluation
  • 4.2.3 Growing Integration Of Real-World Evidence In Drug Discovery
  • 4.2.4 Expansion Of Precision Medicine-Oriented Repositioning
  • 4.2.5 Enhanced Collaboration Between Pharma And Cros

5. Drug Repositioning Service Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biotechnology Firms
• 5.3 Contract Research Organizations
• 5.4 Academic Research Institutions
• 5.5 Hospitals And Ambulatory Surgical Centers

6. Drug Repositioning Service Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Drug Repositioning Service Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Drug Repositioning Service PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Drug Repositioning Service Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Drug Repositioning Service Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Drug Repositioning Service Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Drug Repositioning Service Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Drug Repositioning Service Market Segmentation

• 9.1. Global Drug Repositioning Service Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Generic Drugs, Clinical Trial Failed Drugs
• 9.2. Global Drug Repositioning Service Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Other Therapeutic Area
• 9.3. Global Drug Repositioning Service Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic Research Institutions, Hospitals And Ambulatory Surgical Centers
• 9.4. Global Drug Repositioning Service Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule Drugs, Biologics, Biosimilars, Peptide-Based Drugs
• 9.5. Global Drug Repositioning Service Market, Sub-Segmentation Of Clinical Trial Failed Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Phase I Failed Drugs, Phase II Failed Drugs, Phase III Failed Drugs, Safety-Related Failed Drugs, Efficacy-Related Failed Drugs

10. Drug Repositioning Service Market Regional And Country Analysis

• 10.1. Global Drug Repositioning Service Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Drug Repositioning Service Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Drug Repositioning Service Market

• 11.1. Asia-Pacific Drug Repositioning Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Drug Repositioning Service Market

• 12.1. China Drug Repositioning Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Drug Repositioning Service Market

• 13.1. India Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Drug Repositioning Service Market

• 14.1. Japan Drug Repositioning Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Drug Repositioning Service Market

• 15.1. Australia Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Drug Repositioning Service Market

• 16.1. Indonesia Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Drug Repositioning Service Market

• 17.1. South Korea Drug Repositioning Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Drug Repositioning Service Market

• 18.1. Taiwan Drug Repositioning Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Drug Repositioning Service Market

• 19.1. South East Asia Drug Repositioning Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Drug Repositioning Service Market

• 20.1. Western Europe Drug Repositioning Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Drug Repositioning Service Market

• 21.1. UK Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Drug Repositioning Service Market

• 22.1. Germany Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Drug Repositioning Service Market

• 23.1. France Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Drug Repositioning Service Market

• 24.1. Italy Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Drug Repositioning Service Market

• 25.1. Spain Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Drug Repositioning Service Market

• 26.1. Eastern Europe Drug Repositioning Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Drug Repositioning Service Market

• 27.1. Russia Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Drug Repositioning Service Market

• 28.1. North America Drug Repositioning Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Drug Repositioning Service Market

• 29.1. USA Drug Repositioning Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Drug Repositioning Service Market

• 30.1. Canada Drug Repositioning Service Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Drug Repositioning Service Market

• 31.1. South America Drug Repositioning Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Drug Repositioning Service Market

• 32.1. Brazil Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Drug Repositioning Service Market

• 33.1. Middle East Drug Repositioning Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Drug Repositioning Service Market

• 34.1. Africa Drug Repositioning Service Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Drug Repositioning Service Market, Segmentation By Type, Segmentation By Therapeutic Area, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Drug Repositioning Service Market Regulatory and Investment Landscape

36. Drug Repositioning Service Market Competitive Landscape And Company Profiles

• 36.1. Drug Repositioning Service Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Drug Repositioning Service Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Drug Repositioning Service Market Company Profiles
  • 36.3.1. Recursion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Excelra Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. LifeArc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Cosmos Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Fios Genomics Overview, Products and Services, Strategy and Financial Analysis

37. Drug Repositioning Service Market Other Major And Innovative Companies

• Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited

38. Global Drug Repositioning Service Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Drug Repositioning Service Market

40. Drug Repositioning Service Market High Potential Countries, Segments and Strategies

• 40.1 Drug Repositioning Service Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Drug Repositioning Service Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Drug Repositioning Service Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer